Joanne Holland
Technik-/Wissenschafts-/F&E-Leiter bei CONDUIT PHARMACEUTICALS INC.
Profil
Joanne Holland is the founder of Nuformix Plc, which was founded in 2008.
She held the title of Executive Director in 2021.
Currently, Dr. Holland is the Chief Scientific Officer at Conduit Pharmaceuticals, Inc. since 2024.
Previously, she worked at Nuformix Technologies Ltd.
as the Director, Chief Scientific & Technology Officer from 2008 to 2021.
Dr. Holland obtained a doctorate degree from the University of Leeds.
Aktive Positionen von Joanne Holland
| Unternehmen | Position | Beginn |
|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.03.2024 |
Ehemalige bekannte Positionen von Joanne Holland
| Unternehmen | Position | Ende |
|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 31.05.2021 |
| NUFORMIX PLC | Gründer | 31.05.2021 |
Ausbildung von Joanne Holland
| University of Leeds | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
